Quantcast

Latest Adalimumab Stories

2010-07-28 09:00:00

WALTHAM, Mass., July 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the rheumatoid arthritis (RA) drug market, the uptake of alternative biologics such as Roche/Chugai's Actemra/RoActemra will erode the market share of TNF-alpha inhibitors over the next decade.

2010-06-02 04:30:00

LOS ANGELES, June 2 /PRNewswire/ -- Two new studies suggest that excess levels of a protein associated with inflammation, TNF, may produce cognitive decline. TNF regulates both inflammation and brain function.

2010-05-26 08:26:00

EXTON, Pa., May 26 /PRNewswire/ -- BioTrends released the final wave of LaunchTrends(®): Stelara, a three wave syndicated report that has been tracking the uptake of the product since launch.

2010-05-06 07:00:00

EXTON, Pa., May 6 /PRNewswire/ -- BioTrends is pleased to announce the publication of a new syndicated report, TreatmentTrends®: Rheumatoid Arthritis. This report covers the use of biologics for the treatment of rheumatoid arthritis (RA).

2010-05-02 23:01:00

LONDON, May 3, 2010 /PRNewswire/ -- The rheumatoid arthritis treatment Humira will replace Lipitor as the world's biggest-selling drug in 2016, but a familiar name, Pfizer, will still be the biggest seller of medicines after the patent cliff according to the World Preview 2016 report published today by EvaluatePharma, the premier provider of pharma and biotech analysis. The cancer treatment Avastin had been widely expected to emerge as the biggest blockbuster drug following patent expiry...

2010-04-14 07:00:00

WALTHAM, Mass., April 14 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that for the treatment of Crohn's disease, a novel oral drug for the treatment of moderate to severe Crohn's disease would earn 40 percent patient share according surveyed U.S.

2010-04-07 11:30:00

WALTHAM, Mass., April 7 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed gastroenterologists estimate that (assuming no new data on adverse events emerge) they will treat fewer Crohn's disease patients with Centocor Ortho Biotech/Merck/Mitsubishi Tanabe's Remicade by the end of 2010, while the percentage of biologics-treated patients receiving Abbott/Eisai's Humira will increase to 36 percent.

2010-03-23 07:00:00

WALTHAM, Mass., March 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed dermatologists view Abbott/Eisai's Humira as the most efficacious therapy for the treatment of moderate to severe psoriasis.

2010-03-04 13:00:00

Dermatologists explain why new research finds that psoriasis extends beyond its classification as a chronic skin condition and is linked to serious health risks MIAMI, March 4 /PRNewswire-USNewswire/ -- For the approximately 7.5 million Americans affected by psoriasis, the thick, red, scaly, itchy plaques it causes only scratch the surface when it comes to the overall implications of this disease.


Word of the Day
ecotone
  • A transitional zone between two communities containing the characteristic species of each.
The word 'ecotone' comes 'eco-' plus a Greek root meaning 'tension'.